Invesaro

Stocks Health care CMND

NASDAQ · Health care

Clearmind Medicine Inc. (CMND)

It posted a net loss of $3.9M. At October 31, 2025 it held $3.9M in cash.

What Clearmind Medicine Inc. does

Clearmind Medicine Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CMND.

Revenue and profit by year

Net income
FY21: -$2.7M -$2.7M FY21FY23: -$6.9M -$6.9M FY23FY23: -$8.6M -$8.6M FY23FY24: -$5.3M -$5.3M FY24FY25: -$3.9M -$3.9M FY25

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2025n/an/a-$3.9M-$30.35n/a
2024n/an/a-$5.3M-$67.80n/a
2023n/an/a-$8.6M-$1,703.04n/a
2023n/an/a-$6.9M-$6,363.80-$3.7M
2021n/an/a-$2.7M-$3,526.07-$2.1M

Full financial statements: income, balance sheet and cash flow

Latest SEC filings

What Clearmind Medicine Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. September 23, 2026
  2. September 17, 2026
  3. September 14, 2026
  4. September 10, 2026
  5. September 8, 2026
  6. September 4, 2026
  7. September 2, 2026
  8. September 1, 2026
  9. August 24, 2026
  10. August 12, 2026

Recent insider filings (Forms 3, 4 and 144): 5, the latest on June 18, 2026. Insider transactions on SEC

Insider trades

What the people running Clearmind Medicine Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)
$0
last 90 days
Sold
$0
last 90 days
DateInsiderWhatSharesPriceValueFiling
June 16, 2026 Hrt Financial LP10% owner Sold 22,139 $3.31 $73.2K Form 4
June 15, 2026 Hrt Financial LP10% owner Sold 3,183 $3.32 $10.6K Form 4
June 12, 2026 Hrt Financial LP10% owner Sold 2,102 $3.36 $7.1K Form 4
June 11, 2026 Hrt Financial LP10% owner Sold 225,191 $0.12 $27.7K Form 4
June 10, 2026 Hrt Financial LP10% owner Bought 2,159,052 $0.15 $330.3K Form 4

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns CMND

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

HolderOf classSharesFiled
Richard Abbe13G, passive with 2 related filers 9.99% 346,667 August 12, 2026

Latest filings below 5%: L.I.A. Pure Capital Ltd. 0% (May 15, 2026); Capitalink Ltd. 0% (May 15, 2026).

Largest institutional holders

No Form 13F positions imported for this company yet.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

1 insiders reported holding 184,845 shares in total, about $148.4K at the last price.

HolderSharesAs of
Hrt Financial LP10% owner 184,845 June 16, 2026

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about CMND

What does Clearmind Medicine Inc. do?

Clearmind Medicine Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CMND.

Is Clearmind Medicine Inc. profitable?

No. In fiscal 2025 it reported a net loss of $3.9M.

When did Clearmind Medicine Inc. last report?

Its newest filing of any kind is the foreign issuer update from September 23, 2026.

Similar companies

Compare CMND with

Compare CMND with any company

Follow CMND

Get an email when Clearmind Medicine Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CMND: get an email when it files

Where the numbers come from

Financial figures are the values Clearmind Medicine Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.